Insiders who reported open-market trades in the last 12 months at the companies J. Kevin Buchi files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Nikita Shah - $4.14M in AMRX purchases and sales in the last 12 months
Jason B. Daly - $3.77M in AMRX purchases and sales in the last 12 months
John Kiely - $882K in AMRX purchases and sales in the last 12 months
Ted C. Nark - $586K in AMRX purchases and sales in the last 12 months
Deborah M. Autor - $451K in AMRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
J. Kevin Buchi is a corporate insider, tracked as Director of Amneal Pharmaceuticals, Inc. (AMRX). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has J. Kevin Buchi submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
J. Kevin Buchi is Director of Amneal Pharmaceuticals, Inc. (AMRX). 8 SEC Form 4 filings on record going back to 2024, most recently on 21 September 2026.
Recent transactions
6
The latest 6 SEC Form 4 transactions reported by J. Kevin Buchi.
InsiderAlpha's records for J. Kevin Buchi go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
